Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Curr Med Chem ; 30(7): 841-856, 2023.
Article in English | MEDLINE | ID: mdl-35761503

ABSTRACT

Fibroblast growth factor 23 (FGF23) is a new endocrine product discovered in the past decade. In addition to being related to bone diseases, it has also been found to be related to kidney metabolism and parathyroid metabolism, especially as a biomarker and a key factor to be used in kidney diseases. FGF23 is upregulated as early as the second and third stages of chronic kidney disease (CKD) in response to relative phosphorus overload. The early rise of FGF23 has a protective effect on the body and is essential for maintaining phosphate balance. However, with the decline in renal function, eGFR (estimated glomerular filtration rate) declines, and the phosphorus excretion effect caused by FGF23 is weakened. It eventually leads to a variety of complications, such as bone disease (Chronic Kidney Disease-Mineral and Bone Metabolism Disorder), vascular calcification (VC), and more. Monoclonal antibodies against FGF23 are currently used to treat genetic diseases with increased FGF23. CKD is also a state of increased FGF23. This article reviews the current role of FGF23 in CKD and discusses the crosstalk between various organs under CKD conditions and FGF23. Studying the effect of hyperphosphatemia on different organs of CKD is important. The prospect of FGF23 for therapy is also discussed.


Subject(s)
Bone Diseases, Metabolic , Chronic Kidney Disease-Mineral and Bone Disorder , Fibroblast Growth Factor-23 , Renal Insufficiency, Chronic , Humans , Bone Diseases, Metabolic/complications , Bone Diseases, Metabolic/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Phosphates , Phosphorus , Renal Insufficiency, Chronic/metabolism , Fibroblast Growth Factor-23/metabolism
2.
Front Endocrinol (Lausanne) ; 13: 1000261, 2022.
Article in English | MEDLINE | ID: mdl-36246904

ABSTRACT

Polycystic ovary syndrome is an endocrinopathy that mainly affects adolescent girls and young women of childbearing age. In girls, the presence of clinical and biochemical symptoms of hyperandrogenism should be particularly considered. The role of vitamin D deficiency in insulin resistance, inflammation, dyslipidemia, and obesity, i.e. in diseases associated with PCOS, has been investigated, which may suggest its involvement in the pathophysiology of the syndrome. Leptin has been shown to stimulate the formation of FGF23 in bones. There is a relationship between the incidence of dyslipidemia, adipose tissue mass and the concentration of fibroblast growth factor 23. The main aim of the presented research project is to assess the concentration of vitamin D, calcium, and selected hormones as well as the concentration of adipokines (leptin) in girls diagnosed with polycystic ovary syndrome. Materials and methods: The study included a population of 85 girls and young women aged 14 to 22 years. The study group included 37 girls who were diagnosed with polycystic ovary syndrome according to the modified Rotterdam's criteria. The control group consisted of 48 completely healthy girls. In the first stage of the study participants were required to answer background questions. Next, anthropometric measurements were performed. The laboratory tests assessed: leptin, FGF23, FSH, SHGB, total testosterone, DHEA-S, 25-OH-D3, PTH, calcium, androstadiene, AMH, glucose, insulin. Results: The vitamin D level in the group with polycystic ovary syndrome was lower than in the control group, but there was no statistically significant difference. The level of anti-Müllerian hormone was significantly higher in the group of girls diagnosed with PCOS compared to the control group. Statistically significant differences between both groups were also noted in the HOMA-IR value. The concentration of calcium, parathyroid hormone, FGF23 and leptin in the study and control groups showed no statistically significant difference. Conclusions: In the studied group of girls with PCOS, no correlation between the level of vitamin D and selected parameters such as: AMH leptin, HOMA-IR and FGF23 was confirmed. On this basis, it can be assumed that additional vitamin D supplementation would not reduce the symptoms of polycystic ovary syndrome.


Subject(s)
Fibroblast Growth Factor-23 , Leptin , Polycystic Ovary Syndrome , Vitamin D , Adipokines , Adolescent , Androstadienes , Anti-Mullerian Hormone , Calcium , Dehydroepiandrosterone , Female , Fibroblast Growth Factor-23/metabolism , Follicle Stimulating Hormone , Glucose , Humans , Insulin , Leptin/metabolism , Parathyroid Hormone , Polycystic Ovary Syndrome/complications , Testosterone , Vitamin D/metabolism , Vitamins , Young Adult
3.
Nat Rev Endocrinol ; 18(6): 366-384, 2022 06.
Article in English | MEDLINE | ID: mdl-35484227

ABSTRACT

X-linked hypophosphataemia (XLH) is the most frequent cause of hypophosphataemia-associated rickets of genetic origin and is associated with high levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23). In addition to rickets and osteomalacia, patients with XLH have a heavy disease burden with enthesopathies, osteoarthritis, pseudofractures and dental complications, all of which contribute to reduced quality of life. This Consensus Statement presents the outcomes of a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, and provides robust clinical evidence on management in XLH, with an emphasis on patients' experiences and needs. During growth, conventional treatment with phosphate supplements and active vitamin D metabolites (such as calcitriol) improves growth, ameliorates leg deformities and dental manifestations, and reduces pain. The continuation of conventional treatment in symptom-free adults is still debated. A novel therapeutic approach is the monoclonal anti-FGF23 antibody burosumab. Although promising, further studies are required to clarify its long-term efficacy, particularly in adults. Given the diversity of symptoms and complications, an interdisciplinary approach to management is of paramount importance. The focus of treatment should be not only on the physical manifestations and challenges associated with XLH and other FGF23-mediated hypophosphataemia syndromes, but also on the major psychological and social impact of the disease.


Subject(s)
Familial Hypophosphatemic Rickets , Fibroblast Growth Factor-23 , Osteoarthritis , Wasting Syndrome , Adult , Animals , Familial Hypophosphatemic Rickets/diagnosis , Familial Hypophosphatemic Rickets/drug therapy , Familial Hypophosphatemic Rickets/genetics , Familial Hypophosphatemic Rickets/metabolism , Fibroblast Growth Factor-23/metabolism , Humans , Osteoarthritis/diagnosis , Osteoarthritis/drug therapy , Osteoarthritis/genetics , Osteoarthritis/metabolism , Quality of Life , Wasting Syndrome/diagnosis , Wasting Syndrome/drug therapy , Wasting Syndrome/genetics , Wasting Syndrome/metabolism
4.
Nutrients ; 13(12)2021 Dec 17.
Article in English | MEDLINE | ID: mdl-34960084

ABSTRACT

High plasma fibroblast growth factor 23 (FGF23) and low potassium intake have each been associated with incident hypertension. We recently demonstrated that potassium supplementation reduces FGF23 levels in pre-hypertensive individuals. The aim of the current study was to address whether 24-h urinary potassium excretion, reflecting dietary potassium intake, is associated with FGF23, and whether FGF23 mediates the association between urinary potassium excretion and incident hypertension in the general population. At baseline, 4194 community-dwelling individuals without hypertension were included. Mean urinary potassium excretion was 76 (23) mmol/24 h in men, and 64 (20) mmol/24 h in women. Plasma C-terminal FGF23 was 64.5 (54.2-77.8) RU/mL in men, and 70.3 (56.5-89.5) RU/mL in women. Urinary potassium excretion was inversely associated with FGF23, independent of age, sex, urinary sodium excretion, bone and mineral parameters, inflammation, and iron status (St. ß -0.02, p < 0.05). The lowest sex-specific urinary potassium excretion tertile (HR 1.18 (95% CI 1.01-1.37)), and the highest sex-specific tertile of FGF23 (HR 1.17 (95% CI 1.01-1.37)) were each associated with incident hypertension, compared with the reference tertile. FGF23 did not mediate the association between urinary potassium excretion and incident hypertension. Increasing potassium intake, and reducing plasma FGF23 could be independent targets to reduce the risk of hypertension in the general population.


Subject(s)
Fibroblast Growth Factor-23/blood , Hypertension/prevention & control , Potassium, Dietary/administration & dosage , Potassium, Dietary/pharmacology , Potassium/urine , Adult , Cohort Studies , Female , Fibroblast Growth Factor-23/genetics , Fibroblast Growth Factor-23/metabolism , Gene Expression Regulation/drug effects , Humans , Hypertension/urine , Male , Middle Aged , Risk Factors
5.
Clin Sci (Lond) ; 135(15): 1915-1927, 2021 08 13.
Article in English | MEDLINE | ID: mdl-34374422

ABSTRACT

The klotho gene, named after a Greek goddess who spins the thread of life, was identified as a putative 'ageing-suppressor' gene. Klotho-deficient mice exhibit complex ageing-like phenotypes including hypogonadism, arteriosclerosis (vascular calcification), cardiac hypertrophy, osteopenia, sarcopenia, frailty, and premature death. Klotho protein functions as the obligate co-receptor for fibroblast growth factor-23 (FGF23), a bone-derived hormone that promotes urinary phosphate excretion in response to phosphate intake. Thus, Klotho-deficient mice suffer not only from accelerated ageing but also from phosphate retention due to impaired phosphate excretion. Importantly, restoration of the phosphate balance by placing Klotho-deficient mice on low phosphate diet rescued them from premature ageing, leading us to the notion that phosphate accelerates ageing. Because the extracellular fluid is super-saturated in terms of phosphate and calcium ions, an increase in the phosphate concentration can trigger precipitation of calcium-phosphate. In the blood, calcium-phosphate precipitated upon increase in the blood phosphate concentration is adsorbed by serum protein fetuin-A to form colloidal nanoparticles called calciprotein particles (CPPs). In the urine, CPPs appear in the renal tubular fluid when FGF23 increases phosphate load excreted per nephron. CPPs can induce cell damage, ectopic calcification, and inflammatory responses. CPPs in the blood can induce arteriosclerosis and non-infectious chronic inflammation, whereas CPPs in the urine can induce renal tubular damage and interstitial inflammation/fibrosis. Thus, we propose that CPPs behave like a pathogen that accelerates ageing and should be regarded as a novel therapeutic target against age-related disorders including chronic kidney disease.


Subject(s)
Aging/metabolism , Calcium Phosphates/metabolism , Fibroblast Growth Factor-23/metabolism , Klotho Proteins/metabolism , Nanoparticles , Phosphorus/metabolism , alpha-2-HS-Glycoprotein/metabolism , Age Factors , Aging/pathology , Animals , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Cardiovascular Diseases/physiopathology , Humans , Kidney/metabolism , Kidney/pathology , Kidney/physiopathology , Renal Elimination , Renal Insufficiency, Chronic/metabolism , Renal Insufficiency, Chronic/pathology , Renal Insufficiency, Chronic/physiopathology
6.
Bioengineered ; 12(1): 4464-4474, 2021 12.
Article in English | MEDLINE | ID: mdl-34304712

ABSTRACT

Spontaneous senile osteoporosis severely threatens the health of the senior population which has emerged as a severe issue for society. A SAMP6 mouse model was utilized to estimate the impact of intragastrically administered Astragalus Membranaceus (AR) on spontaneous senile osteoporosis. Bone mineral density (BMD) and bone microstructure were measured using Micro-CT; contents of calcium and phosphorus were determined with the colorimetric method; and gene and protein expressions of fibroblast growth factor 23 (FGF23), Klotho, Vitamin D receptor (VDR), CYP27B1 and CYP24A1 were detected using qPCR, Western blot and ELISA assays, respectively. The findings indicated that AR could improve the femoral BMD and bone microstructure, elevate the contents of calcium and phosphorus, and increase the expression of Klotho, VDR, and CYP27B1 whereas decreasing the expression of FGF23 and CYP24A1 in SAMP6 mice in a dose independent manner. The present study has demonstrated that AR can promote osteogenesis and alleviate osteoporosis. It is also expected to provide a new insight for the treatment of spontaneous senile osteoporosis and to serve as a research basis for AR application.


Subject(s)
Astragalus propinquus , Fibroblast Growth Factor-23/genetics , Osteoporosis/metabolism , Plant Extracts/pharmacology , Receptors, Calcitriol/genetics , Animals , Bone Density/drug effects , Cells, Cultured , Femur/cytology , Femur/drug effects , Femur/metabolism , Fibroblast Growth Factor-23/metabolism , Klotho Proteins/genetics , Klotho Proteins/metabolism , Male , Mesenchymal Stem Cells/drug effects , Mice , Receptors, Calcitriol/metabolism , Signal Transduction/drug effects
7.
Front Endocrinol (Lausanne) ; 12: 641543, 2021.
Article in English | MEDLINE | ID: mdl-33815294

ABSTRACT

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidisciplinary group of Belgian experts convened to discuss translation of international best available evidence into locally feasible consensus recommendations. Patients with XLH may present to a wide array of primary, secondary and tertiary care physicians, among whom awareness of the disease should be raised. XLH has a very broad differential-diagnosis for which clinical features, biochemical and genetic testing in centers of expertise are recommended. Optimal care requires a multidisciplinary approach, guided by an expert in metabolic bone diseases and involving (according to the individual patient's needs) pediatric and adult medical specialties and paramedical caregivers, including but not limited to general practitioners, dentists, radiologists and orthopedic surgeons. In children with severe or refractory symptoms, FGF23 inhibition using burosumab may provide superior outcomes compared to conventional medical therapy with phosphate supplements and active vitamin D analogues. Burosumab has also demonstrated promising results in adults on certain clinical outcomes such as pseudofractures. In summary, this work outlines recommendations for clinicians and policymakers, with a vision for improving the diagnostic and therapeutic landscape for XLH patients in Belgium.


Subject(s)
Familial Hypophosphatemic Rickets/diagnosis , Familial Hypophosphatemic Rickets/therapy , Fibroblast Growth Factor-23/metabolism , Mutation , PHEX Phosphate Regulating Neutral Endopeptidase/genetics , Societies, Medical/organization & administration , Alkaline Phosphatase/metabolism , Antibodies, Monoclonal, Humanized/administration & dosage , Belgium , Consensus , Familial Hypophosphatemic Rickets/complications , Familial Hypophosphatemic Rickets/genetics , Humans , Hypophosphatemia/complications , Hypophosphatemia/genetics , Interdisciplinary Communication , Osteomalacia/complications , Osteomalacia/genetics , Severity of Illness Index , Treatment Outcome , Vitamin D
SELECTION OF CITATIONS
SEARCH DETAIL